Population-level uptake of neoadjuvant chemotherapy for stage IVB endometrial cancer.

[1]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[2]  L. Havrilesky,et al.  Neoadjuvant chemotherapy for advanced stage endometrial cancer: A systematic review , 2021, Gynecologic Oncology Reports.

[3]  B. Somer,et al.  Comparison of Chemotherapy vs Chemotherapy Plus Total Hysterectomy for Women With Uterine Cancer With Distant Organ Metastasis , 2021, JAMA network open.

[4]  A. Melamed,et al.  Use and outcomes of neoadjuvant chemotherapy for metastatic uterine cancer. , 2021, Gynecologic oncology.

[5]  L. Havrilesky,et al.  Primary cytoreductive surgery for advanced stage endometrial cancer: A systematic review and meta-analysis. , 2021, American journal of obstetrics and gynecology.

[6]  T. Pawlik,et al.  STROBE Reporting Guidelines for Observational Studies. , 2021, JAMA surgery.

[7]  A. Neugut,et al.  Association of Neoadjuvant Chemotherapy With Overall Survival in Women With Metastatic Endometrial Cancer , 2020, JAMA network open.

[8]  L. Chambers,et al.  Impact of treatment modality on overall survival in women with advanced endometrial cancer: A National Cancer Database analysis. , 2020, Gynecologic oncology.

[9]  A. Sood,et al.  Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer. , 2020, Gynecologic oncology.

[10]  Jubilee Brown,et al.  When to Operate, Hesitate and Reintegrate: Society of Gynecologic Oncology Surgical Considerations during the COVID-19 Pandemic , 2020, Gynecologic Oncology.

[11]  M. Kaneuchi,et al.  Survival outcome and perioperative complication related to neoadjuvant chemotherapy with carboplatin and paclitaxel for advanced ovarian cancer: A systematic review and meta-analysis. , 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[12]  M. Frey,et al.  Neoadjuvant chemotherapy in patients with advanced endometrial cancer , 2019, Cancer Chemotherapy and Pharmacology.

[13]  J. Kwon,et al.  Neoadjuvant chemotherapy followed by surgery for advanced-stage endometrial cancer. , 2019, Current oncology.

[14]  A. Sayasneh,et al.  Advanced stage (IIIC/IV) endometrial cancer: Role of cytoreduction and determinants of survival. , 2019, European journal of obstetrics, gynecology, and reproductive biology.

[15]  G. Bogani,et al.  Neoadjuvant chemotherapy followed by interval debulking surgery for unresectable stage IVB Serous endometrial cancer , 2018, Tumori.

[16]  M. Yunokawa,et al.  Survival outcome of women with stage IV uterine carcinosarcoma who received neoadjuvant chemotherapy followed by surgery , 2018, Journal of surgical oncology.

[17]  R. Broaddus,et al.  Factors prognostic of survival in advanced-stage uterine serous carcinoma. , 2017, Gynecologic oncology.

[18]  T. Kasamatsu,et al.  Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602. , 2016, European journal of cancer.

[19]  G. Scambia,et al.  Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome. , 2016, European journal of cancer.

[20]  E. Darai,et al.  Endometrial cancer , 2016, The Lancet.

[21]  H. Kitchener,et al.  Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial , 2015, The Lancet.

[22]  D. Mutch,et al.  Neoadjuvant Chemotherapy Versus Primary Cytoreductive Surgery for Stage IV Uterine Serous Carcinoma , 2015, International Journal of Gynecologic Cancer.

[23]  T. Kasamatsu,et al.  Status of treatment for the overall population of patients with stage IVb endometrial cancer, and evaluation of the role of preoperative chemotherapy: a retrospective multi-institutional study of 426 patients in Japan. , 2013, Gynecologic oncology.

[24]  Jenny Chang,et al.  Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. , 2013, Gynecologic oncology.

[25]  R. Bristow,et al.  Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining 'optimal' residual disease. , 2012, Gynecologic oncology.

[26]  G. Kenter,et al.  Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. , 2010, The New England journal of medicine.

[27]  B. van Calster,et al.  Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment? , 2009, British Journal of Cancer.

[28]  S. Pecorelli.  Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium , 2009 .

[29]  G. Scambia,et al.  A Laparoscopy-Based Score To Predict Surgical Outcome in Patients With Advanced Ovarian Carcinoma: A Pilot Study , 2006, Annals of Surgical Oncology.

[30]  E. Feuer,et al.  Permutation tests for joinpoint regression with applications to cancer rates. , 2000, Statistics in medicine.

[31]  J. Taxy,et al.  Neoadjuvant chemotherapy in uterine papillary serous carcinoma. , 1996, Gynecologic oncology.

[32]  B. Hankey,et al.  Completeness of hospital cancer case reporting from the SEER program of the national cancer institute , 1995 .